110 related articles for article (PubMed ID: 1513800)
1. Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin.
Friess H; Büchler M; Krüger M; Beger HG
Pancreas; 1992; 7(5):516-21. PubMed ID: 1513800
[TBL] [Abstract][Full Text] [Related]
2. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer.
Friess H; Büchler M; Beglinger C; Weber A; Kunz J; Fritsch K; Dennler HJ; Beger HG
Pancreas; 1993 Sep; 8(5):540-5. PubMed ID: 8302789
[TBL] [Abstract][Full Text] [Related]
3. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
Doberauer C; Niederle N; Schmidt CG
Cancer; 1988 Aug; 62(3):474-8. PubMed ID: 3134119
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
Grifoni R; Pierangeli T
Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
7. Long-term results with the Gn-RH analogue, buserelin, in metastatic prostate cancer.
Maffezzini M; Villa E; Broglia L; Francesca F; Rigatti P
Tumori; 1990 Feb; 76(1):66-8. PubMed ID: 2108517
[TBL] [Abstract][Full Text] [Related]
8. Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin).
Sperti C; Pasquali C; Catalini S; Cappellazzo F; Bonadimani B; Militello C; Pedrazzoli S
Eur J Surg Oncol; 1992 Jun; 18(3):267-71. PubMed ID: 1535051
[TBL] [Abstract][Full Text] [Related]
9. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
10. Treatment of prostatic cancer with LH-RH analogues.
Borgmann V; Nagel R; Al-Abadi H; Schmidt-Gollwitzer M
Prostate; 1983; 4(6):553-68. PubMed ID: 6415628
[TBL] [Abstract][Full Text] [Related]
11. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
12. LH-RH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Gruppo Ligure per lo Studio del Pancreas.
Allegretti A; Lionetto R; Saccomanno S; Paganuzzi M; Onetto M; Martinoli C; Rollandi G; Marugo M; Fazzuoli L; Pugliese V
Oncology; 1993; 50(2):77-80. PubMed ID: 8451039
[TBL] [Abstract][Full Text] [Related]
13. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
[TBL] [Abstract][Full Text] [Related]
14. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
15. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life.
Presant CA; Soloway MS; Klioze SS; Yakabow A; Presant SN; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Todd B
Cancer; 1987 May; 59(10):1713-6. PubMed ID: 3103904
[TBL] [Abstract][Full Text] [Related]
16. CA-125 monitored therapy with GnRH analogue of pelvic endometriosis.
Negri P; Ricciardelli MA; Tomasi A; Grechi E; Fortini RM
Acta Eur Fertil; 1992; 23(4):171-4. PubMed ID: 1343472
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the luteinizing hormone-releasing activities of synthetic chicken luteinizing hormone-releasing hormone (LH-RH), synthetic porcine LH-RH, and buserelin, an LH-RH analogue, in the domestic fowl.
Sterling RJ; Sharp PJ
Gen Comp Endocrinol; 1984 Sep; 55(3):463-71. PubMed ID: 6432627
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT
Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
